Recombinant Human ADCY3 293 Cell Lysate
Cat.No. : | ADCY3-9021HCL |
- Specification
- Gene Information
- Related Products
- Download
Description : | Antigen standard for adenylate cyclase 3 (ADCY3) is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection. |
Source : | HEK 293 cells |
Species : | Human |
Components : | This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol). |
Size : | 0.1 mg |
Storage Instruction : | Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment. |
Applications : | ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane. |
Tag : | Non |
Gene Name : | ADCY3 adenylate cyclase 3 [ Homo sapiens ] |
Official Symbol : | ADCY3 |
Synonyms : | ADCY3; adenylate cyclase 3; adenylate cyclase type 3; AC3; AC-III; adenylyl cyclase 3; ATP pyrophosphate-lyase 3; adenylate cyclase type III; adenylyl cyclase, type III; adenylate cyclase, olfactive type; KIAA0511; |
Gene ID : | 109 |
mRNA Refseq : | NM_004036 |
Protein Refseq : | NP_004027 |
MIM : | 600291 |
UniProt ID : | O60266 |
Chromosome Location : | 2p24-p22 |
Pathway : | Activation of GABAB receptors, organism-specific biosystem; Activation of NMDA receptor upon glutamate binding and postsynaptic events, organism-specific biosystem; Adenylate cyclase activating pathway, organism-specific biosystem; Adenylate cyclase inhibitory pathway, organism-specific biosystem; Aquaporin-mediated transport, organism-specific biosystem; Bile secretion, organism-specific biosystem; Bile secretion, conserved biosystem; |
Function : | ATP binding; GTPase activity; adenylate cyclase activity; calcium- and calmodulin-responsive adenylate cyclase activity; calmodulin binding; metal ion binding; nucleotide binding; |
Products Types
◆ Recombinant Protein | ||
ADCY3-3312H | Recombinant Human ADCY3 protein, His-GST-tagged | +Inquiry |
ADCY3-3173H | Recombinant Human ADCY3, His-tagged | +Inquiry |
ADCY3-328H | Recombinant Human ADCY3 Protein, GST-tagged | +Inquiry |
ADCY3-6925H | Recombinant Human ADCY3 protein, His & T7-tagged | +Inquiry |
ADCY3-7540Z | Recombinant Zebrafish ADCY3 | +Inquiry |
Related Gene
Not For Human Consumption!
Inquiry
- Reviews
- Q&As
Q&As (14)
Ask a questionYes, personalized medicine approaches could potentially be developed based on ADCY3 expression levels. Measuring ADCY3 expression could help identify patients who are more likely to respond to certain treatments and stratify patients into specific subgroups for more targeted therapies.
Yes, targeting ADCY3 with drugs could potentially have side effects, as cAMP signaling pathways are involved in many cellular processes. It is important to carefully evaluate potential drugs and their effects on other cellular processes to minimize any unwanted side effects.
Yes, ADCY3 research could lead to the development of new drugs that target cAMP signaling in a more specific and effective way than currently available treatments. This could lead to better outcomes for patients with diseases related to metabolism and energy regulation.
ADCY3 protein may be used as a diagnostic biomarker, as its expression may be altered in certain disease states. For example, decreased ADCY3 expression has been observed in patients with polycystic ovary syndrome (PCOS), a common endocrine disorder in women. Detecting changes in ADCY3 expression levels in patient samples could be used to diagnose or monitor PCOS.
ADCY3 protein is unlikely to be used as a therapeutic agent itself, as it is a large protein that would be difficult to deliver to cells in vivo. Instead, drugs that modulate ADCY3 activity or other components of the cAMP signaling pathway may be developed as therapies for various diseases.
ADCY3 protein has potential applications in medicine for the treatment of diseases related to metabolism and energy regulation, such as type 2 diabetes and obesity. Understanding the role of ADCY3 in these diseases could lead to the development of new drug targets and treatments.
ADCY3 protein can be used as a target for developing drugs that modulate cAMP signaling. High-throughput screening methods can be used to identify compounds that interact with ADCY3 or other components of the cAMP signaling pathway. These compounds can then be optimized through medicinal chemistry to create more potent and selective drugs.
Targeting ADCY3 protein or other components of the cAMP signaling pathway has the potential to lead to the development of new therapies for a variety of diseases, including metabolic disorders, cardiovascular diseases, and neurological disorders. By modulating cAMP signaling, these drugs may be able to improve various cellular processes and signaling pathways, leading to improved health outcomes for patients. Additionally, targeting ADCY3 or other components of the cAMP signaling pathway may offer a more personalized approach to treating patients with these diseases.
ADCY3 protein is unlikely to be used in gene therapy, as it is a large protein that would be difficult to deliver to cells in vivo. However, gene therapy approaches that target the ADCY3 gene or other components of the cAMP signaling pathway may be developed in the future.
ADCY3 protein has been implicated in the regulation of energy metabolism and the development of metabolic disorders such as obesity and type 2 diabetes. Studies have shown that decreased ADCY3 expression or activity is associated with obesity and insulin resistance, while increased ADCY3 expression or activity is associated with improved glucose homeostasis and insulin signaling. These findings suggest that targeting ADCY3 or other components of the cAMP signaling pathway may be useful for treating metabolic disorders.
ADCY3 protein is an enzyme that catalyzes the conversion of ATP to cAMP, a second messenger molecule involved in a variety of cellular processes. This activity is stimulated by G protein-coupled receptors (GPCRs), which activate ADCY3 through interactions with G proteins and other signaling proteins. The resulting increase in cAMP levels can then activate downstream effectors, including protein kinase A (PKA) and exchange protein directly activated by cAMP (EPAC), which mediate various cellular responses.
Yes, ADCY3 protein expression levels could potentially be used as a diagnostic marker for diseases such as type 2 diabetes and obesity. This could help with early detection and better monitoring of these conditions.
ADCY3 protein has potential applications in drug discovery, personalized medicine, and diagnostics. It can be used as a target for developing drugs that modulate cAMP signaling, which could be useful for treating a variety of diseases such as metabolic disorders, cardiovascular diseases and neurological disorders. Additionally, knowledge of ADCY3 expression and activity could be used to develop personalized medicine approaches for treating patients with these diseases. ADCY3 protein could also be used as a diagnostic biomarker, as its expression may be altered in certain disease states.
There are currently no FDA-approved drugs that directly target ADCY3. However, several drugs that indirectly modulate cAMP signaling have been approved for use in various diseases, such as asthma, heart failure, and glaucoma.
Ask a Question for All ADCY3 Products
Required fields are marked with *
My Review for All ADCY3 Products
Required fields are marked with *
Inquiry Basket